UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 927

Sortiert nach

Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Journal of internal medicine, 2014-03, Vol.275 (3), p.251-283

2014

Link zum Volltext

Verfügbarkeit prüfen

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review

CNS drugs, 2014-05, Vol.28 (5), p.421-453

2014

Link zum Volltext

Verfügbarkeit prüfen

The role of stress in the pathophysiology of the dopaminergic system

Molecular psychiatry, 2000, Vol.5 (1), p.14-21

2000

Link zum Volltext

Verfügbarkeit prüfen

The future is now: Model-based clinical trial design for Alzheimer's disease

Clinical pharmacology and therapeutics, 2015-03, Vol.97 (3), p.210-214

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries

European review for medical and pharmacological sciences, 2020-05, Vol.24 (10), p.5758

2020

Link zum Volltext

Verfügbarkeit prüfen

1-(2′,4′-dichlorophenyl)-6-methyl- N -cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice

Neurobiology of disease, 2010-01, Vol.37 (1), p.177-185

2010

Link zum Volltext

Verfügbarkeit prüfen

C.08.03 Optimal outcomes for patients with schizophrenia: a focus on functioning

European neuropsychopharmacology, 2010, Vol.20, p.S643-S643

Pani, L

2010

Link zum Volltext

Verfügbarkeit prüfen

Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways

Clinical pharmacology and therapeutics, 2016-12, Vol.100 (6), p.730-742

2016

Link zum Volltext

Verfügbarkeit prüfen

Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review

European review for medical and pharmacological sciences, 2013-02, Vol.17 Suppl 1, p.45

2013

Link zum Volltext

Verfügbarkeit prüfen

Systematic Data Monitoring and Analysis of Cardiovascular Off-label Prescriptions in Pediatrics: Focus on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Beta Blockers

High blood pressure & cardiovascular prevention, 2022-03, Vol.29 (2), p.169-195

2022

Link zum Volltext

Verfügbarkeit prüfen

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

Molecular psychiatry, 2001-11, Vol.6 (6), p.657-664

2001

Link zum Volltext

Verfügbarkeit prüfen

C.08.02 Improving the pharmacokinetic profile of antipsychotics – what difference does it make?

European neuropsychopharmacology, 2008, Vol.18, p.S596-S596

Pani, L

2008

Link zum Volltext

Verfügbarkeit prüfen

S.01.05 What are the advantages of new formulations of antipsychotic drugs?

European neuropsychopharmacology, 2008, Vol.18, p.S156-S156

Pani, L

2008

Link zum Volltext

Verfügbarkeit prüfen

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry

Nutrition, metabolism, and cardiovascular diseases, 2014-12, Vol.24 (12), p.1346-1353

2014

Link zum Volltext

Verfügbarkeit prüfen

Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries ?

Molecular psychiatry, 2000-09, Vol.5 (5), p.467-475

PANI, L

2000

Link zum Volltext

Verfügbarkeit prüfen

C.17.01 Optimizing pharmacokinetic and pharmacodynamic properties of antipsychotics for improved outcomes

European neuropsychopharmacology, 2007, Vol.17, p.S608-S608

Pani, L

2007

Link zum Volltext

Verfügbarkeit prüfen

The need for individualised antipsychotic drug therapy in patients with schizophrenia

European review for medical and pharmacological sciences, 2009-11, Vol.13 (6), p.453

Pani, L

2009

Link zum Volltext

Verfügbarkeit prüfen

PHP99 How to Deal With Decision Uncertainty? The Italian Experience With Managed Entry Agreements

Value in health, 2012-06, Vol.15 (4), p.A31-A31

2012

Link zum Volltext

Verfügbarkeit prüfen

The Italian Medicines Agency Experience With Hta Scientific Advice Activities: A Comprehensive Analysis Of Three Years Of National And International Activities

Value in health, 2014-05, Vol.17 (3), p.A27-A28

2014

Link zum Volltext

Verfügbarkeit prüfen

Subthreshold depression in older subjects: An unmet therapeutic need

The Journal of nutrition, health & aging, 2012-10, Vol.16 (10), p.909-913

2012

Link zum Volltext

Verfügbarkeit prüfen

PIN57 Public Expenditure for Antiretroviral Treatment and Projected Cost-Savings After the Entry of Generic Antiretrovirals in the Italian Pharmaceutical Market

Value in health, 2012-06, Vol.15 (4), p.A247-A247

2012

Link zum Volltext

Verfügbarkeit prüfen

PHP39 The “Weight” of Orphan Drugs in the European Pharmaceutical Policy. A Focus on the Expenditure and the Utilization of Orphan Drugs in Five European Union Countries

Value in health, 2012-06, Vol.15 (4), p.A20-A20

2012

Link zum Volltext

Verfügbarkeit prüfen

A focus on real life data concerning antidiabetic drugs: The experience of aifa monitoring registry

Value in health, 2013-05, Vol.16 (3), p.A174-A174

2013

Link zum Volltext

Verfügbarkeit prüfen

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Molecular psychiatry, 2002-01, Vol.7 (3), p.247-253

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical Implications of Dopamine Research in Schizophrenia

Current medical research and opinion, 2002, Vol.18 (S3), p.s3-s7

Pani, L.

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 927

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(773)
Mit Volltextzugriff
(817)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review

The role of stress in the pathophysiology of the dopaminergic system

The future is now: Model-based clinical trial design for Alzheimer's disease

Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries

1-(2′,4′-dichlorophenyl)-6-methyl- N -cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice

C.08.03 Optimal outcomes for patients with schizophrenia: a focus on functioning

Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways

Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review

Systematic Data Monitoring and Analysis of Cardiovascular Off-label Prescriptions in Pediatrics: Focus on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Beta Blockers

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

C.08.02 Improving the pharmacokinetic profile of antipsychotics – what difference does it make?

S.01.05 What are the advantages of new formulations of antipsychotic drugs?

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry

Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries ?

C.17.01 Optimizing pharmacokinetic and pharmacodynamic properties of antipsychotics for improved outcomes

The need for individualised antipsychotic drug therapy in patients with schizophrenia

PHP99 How to Deal With Decision Uncertainty? The Italian Experience With Managed Entry Agreements

The Italian Medicines Agency Experience With Hta Scientific Advice Activities: A Comprehensive Analysis Of Three Years Of National And International Activities

Subthreshold depression in older subjects: An unmet therapeutic need

PIN57 Public Expenditure for Antiretroviral Treatment and Projected Cost-Savings After the Entry of Generic Antiretrovirals in the Italian Pharmaceutical Market

PHP39 The “Weight” of Orphan Drugs in the European Pharmaceutical Policy. A Focus on the Expenditure and the Utilization of Orphan Drugs in Five European Union Countries

A focus on real life data concerning antidiabetic drugs: The experience of aifa monitoring registry

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Clinical Implications of Dopamine Research in Schizophrenia

Suchergebnisse filtern